Slide 1: DURAVYU in NPDR PAVIA Phase 2 Clinical Trial Topline Results
DURAVYU™ in NPDR PAVIA Phase 2 Clinical Trial Topline Results May 6, 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FD
Slide 2: Legal Disclaimers
Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate
Slide 3: Pipeline represents potential multi billion-dollar opportunities using bioerodible Durasert E
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Pipeline represents potential multi billion-dollar opportunities using our bioerodible Durasert E™ IVT delivery technology DURAVYU™ (vorolanib intravitreal insert) – vorolanib, a selective and patented TKI in Durasert E™ Positive topline Phas
Slide 4: Potential Multi Billion-Dollar Product Opportunities Leveraging Innovative Drug Delivery Technology
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first patient in; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema; GA, geographic atrophy Durasert E™ Programs Indication Discovery Pre-Clin P
Slide 5: Vorolanib Brings a Potential New MOA to Treatment of VEGF-Mediated Retinal Diseases
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growth factor; TIE-2, tyrosine-protein kinase receptor TIE-2; VEGF(R), vascular endothelial growth factor (receptor). Potent and sel
Slide 6: DURAVYU: VEGF Receptor Binding Vorolanib in Bioerodible Durasert E
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Insert is ~1/5000 of vitreous volume Positive efficacy data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials Favorable safety profile with no ocular or systemic DURAVYU-related SAEs reported in ongoing Phase 2 clinical trials
Slide 7: Phase 2 PAVIA Clinical Trial Topline Results
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 PAVIA Clinical Trial Topline Results A Randomized, Multicenter trial VERSUS Sham Control
Slide 8: The PAVIA Clinical Trial in NPDR
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. The PAVIA Clinical Trial in NPDR A clinical trial evaluating two doses of DURAVYU against a sham control as a 9-month therapy Design: Multi-center, randomized, double-masked, single injection of DURAVYU compared to sham control in patients wi
Slide 9: Phase 2 PAVIA is a Randomized, Double-Masked, Single Injection Trial Versus Sham
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU DOSING VISIT SCHEDULED SHAM INJECTION -D21 to -D5 D1 W4 W12 W24 W36 W48 DURAVYU 2mg low dose n=26 DURAVYU 3mg high dose n=25 Control Sham n=26 RANDOMIZATION DURAVYU 1⁰ ENDPOINT UNMASK DATA Phase 2 PAVIA is a Randomized, Double-Masked,
Slide 10: PAVIA Baseline Characteristics Balanced Across Arms
PAVIA Baseline Characteristics Balanced Across Arms ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Control Sham (n=26) DURAVYU 2mg (n=26) DURAVYU 3mg (n=25) Mean age, years (range) 56.9 (29-83) 56.8 (24-73) 60.2 (34-81) Female, % 50.0 46.2 36.0 DRSS score, % Moderately-severe NPDR (score
Slide 11: Phase 2 PAVIA Trial Primary Endpoint: ≥2 step DRSS Improvement
Phase 2 PAVIA Trial Primary Endpoint: Percentage of Patients with a ≥2 step DRSS Improvement ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Percentage of Patients with a ≥2-step DRSS Improvement from Baseline to Nine Months Patients (%) (n=20) (n=
Slide 12: Eyes Treated with DURAVYU had Reduced Rates of Disease Progression at Nine Months
Eyes Treated with DURAVYU had Reduced Rates of Disease Progression at Nine Months ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Percentage of Patients with ≥2-step Worsening Disease from Baseline to Nine Months Patients (%) (n=20) (n=20) (n=21)
Slide 13: ~80% of Eyes Treated with DURAVYU Had Stable or Improved Severity at Nine Months
~80% of Eyes Treated with DURAVYU Had Stable or Improved Severity of Disease at Nine Months ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Percentage of Patients with Stable Or Improved Disease from Baseline to Nine Months Patients (%) (n=20) (n=2
Slide 14: DURAVYU Reduced Rates of NPDR Progression at Nine Months
DURAVYU Reduced Rates of NPDR Progression at Nine Months ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS DRSS, diabetic retinopathy severity scale PERCENTAGES OF PATIENTS WITH ≥1-STEP IMPROVEMENT OR WORSENING IN DRSS FROM BASELINE Patients (%) ≥1-s
Slide 15: DURAVYU Demonstrated a Favorable Safety Profile in the Phase 2 PAVIA Trial
DURAVYU Demonstrated a Favorable Safety Profile in the Phase 2 PAVIA Trial ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of April 25, 2024 SAE, serious adverse event PRELIMINARY DATA – PENDING FINAL ANALYSIS No reported drug-related ocular SAEs Two ocular SAEs reported in a study
Slide 16: Phase 2 PAVIA Trial Demonstrated a Biologic Effect with Favorable Safety and Tolerability
Phase 2 PAVIA Clinical Trial Demonstrated a Biologic Effect with a Favorable Safety and Tolerability Profile ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS SAE, serious adverse event; TEAEs, treatment emergent adverse event Efficacy Safety DURAVYU
Slide 17: DURAVYU in NPDR PAVIA Phase 2 Clinical Trial Topline Results
DURAVYU™ in NPDR PAVIA Phase 2 Clinical Trial Topline Results May 6, 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FD